Synergy Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research and Development 50,630 29,294 13,419 9,559
Sales, General and Admin. 11,681 7,941 6,745 6,562
Non-Recurring Items - 1,000 - -
Other - - - -
Operating Income (62,311) (38,235) (20,164) (16,121)
Income From Continuing Operations
Add'l Income/Expense Items 208 (1,209) 5,709 900
Earnings Before Interest and Tax (62,103) (39,444) (14,455) (15,221)
Interest Expense 21 - 12 -
Earnings Before Tax (62,124) (39,444) (14,467) (15,221)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (62,124) (39,444) (14,467) (15,221)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (62,124) (39,444) (14,467) (15,221)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (62,124) (39,444) (14,467) (15,221)